May 2005
Volume 46, Issue 13
ARVO Annual Meeting Abstract  |   May 2005
Measuring Utility in Glaucoma
Author Affiliations & Notes
  • A. Alm
    Dept of Neuroscience Ophthalmol, University Hospital, Uppsala, Sweden
  • G. Kobelt
    European Health Economics SAS, Speracedes,, France
  • A. Bergström
    Eye Clinic, University Hospital, Lund, Sweden
  • E. Chen
    St.Erik’s Eye Hospital, Stockholm, Sweden
  • C. Lindén
    Eye Clinic, University Hospital, Umeå, Sweden
  • Footnotes
    Commercial Relationships  A. Alm, Allergan, Inc. C; G. Kobelt, Allergan, Inc C; A. Bergström, Allergan, Inc C; E. Chen, Allergan, Inc C; C. Lindén, Allergan, Inc C.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 1947. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      A. Alm, G. Kobelt, A. Bergström, E. Chen, C. Lindén; Measuring Utility in Glaucoma . Invest. Ophthalmol. Vis. Sci. 2005;46(13):1947.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Abstract: : Purpose: Measuring utility using interview–based methods such as standard gamble (SG) or time trade–off (TTO) is resource intensive and time consuming, and difficult to perform for large samples. We performed a pilot study to test whether utilities for different levels of visual field defect in glaucoma could be assessed using a general questionnaire. Methods: 204 patients with ocular hypertension or open–angle glaucoma in Sweden completed a questionnaire that included a utility instrument (EQ–5D). Patients were classified into 5 stages according to damage in the worse eye. Utilities were correlated with visual field damage (MD) and visual acuity (VA), and findings compared to the scores obtained by Brown 1 using TTO. Results: The mean age was 70 and the mean utility was 0.798. Although utility decreased with increasing damage in the worse eye, ranging from 0.83 to 0.73 (MD –2.6 to –26.4) in the 5 stages, the correlation was not significant when controlling for co–morbidity. However, the correlation with MD in the better eye and total VA was significant. VA in the better eye ranged from 0.93 to 0.80, and when controlling for age, utilities were similar to those found by Brown for the same range of VA. Conclusions: Our results confirm the importance of the better eye for measuring utility, and indicate that the EQ–5D is able to discriminate between patients with different levels of total VA, similar to TTO. 1 Brown J. Vision and Quality of Life. Trans Am Ophthalmol Soc 1999; 97:473–511.

Keywords: clinical (human) or epidemiologic studies: health care delivery/economics/manpower • clinical (human) or epidemiologic studies: outcomes/complications • clinical (human) or epidemiologic studies: systems/equipment/techniques 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.